PPAR-γ Ligand Inhibits Nasopharyngeal Carcinoma Cell Proliferation and Metastasis by Regulating E2F2
Table 1
Expressions of E2F2 and PPAR-γ in clinical samples of undifferentiated NPC and NPG and associations with clinicopathological characteristics of undifferentiated NPC samples.
Parameter
N
E2F2
N
PPAR-γ
Low expression
High expression
P value
Low expression
High expression
P value
Histologic type
<0.01
<0.01
NPC
52
19 (36.54)
33 (63.46)
52
37 (71.15)
15 (28.85)
NPG
34
28 (82.35)
6 (17.65)
34
8 (23.53)
26 (76.47)
Gender
0.868
0.377
Male
39
14 (35.90)
25 (64.10)
39
29 (74.36)
10 (25.64)
Female
13
5 (38.46)
8 (61.54)
13
8 (61.54)
5 (38.46)
Age (y)
0.253
0.1
<50
22
10 (45.45)
12 (54.55)
22
13 (59.09)
9 (40.91)
≧50
30
9 (30.00)
21 (70.00)
30
24 (80.00)
6 (20.00)
T classification
0.457
0.33
I-II
35
14 (40.00)
21 (60.00)
35
23 (65.71)
12 (34.29)
III-IV
17
5 (29.41)
12 (70.59)
17
14 (82.35)
3 (17.65
N classification
0.037
0.071
N0-N1
40
18 (45.00)
22 (55.00)
40
26 (65.00)
14 (35.00)
N2-N3
12
1 (8.33)
11 (91.67)
12
11 (91.67)
1 (8.33)
M classification
0.004
0.046
M0
42
19 (45.24)
23 (54.76)
42
27 (64.29)
15 (35.71)
M1
10
0 (0)
10 (100)
10
10 (100)
0 (0)
E2F2 low expression: IOD/Area<0.02; high expression: IOD/Area⩾0.02. PPAR-γ low expression: IOD/Area<0.02; high expression: IOD/Area⩾0.02. Chi-square test.
